A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Trastuzumab-deruxtecan (Primary) ; Abemaciclib; Anastrozole; Atezolizumab; Carboplatin; Docetaxel; Epirubicin; Eribulin; Exemestane; Fulvestrant; Gemcitabine; Letrozole; Paclitaxel; Pertuzumab; Ribociclib; Tamoxifen; Vinorelbine
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms DISCORDANT

03 Oct 2024 Trial phase changed from 4 to 3. Drug Pembrolizumab and Trastuzumab removed and Trastuzumab deruxtecan added in the study protocol. Planned number of patients also increased.
03 Oct 2024 Planned number of patients changed from 250 to 504.
30 Sep 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com